Keeping you up to date with reliable diabetes research, policy & guidance
Insuline glargine has several clinical and quality of life benefits compared with human basal insulin (NPH). However, it is also more costly. Do these benefits justify the additional cost? A new economic evaluation addresses this question. The authors searched the literature for published evaluations. They found seven good quality studies that addressed the issue, though [read the full story…]
The STAR trial investigated the benefits of sensor-augmented pump therapy compared with multiple daily injections (MDI) in adults with type 1 diabetes. This report of results from the trial tries to identify features of the patients who were more likely to experience improved glycaemic control in both group. This might help us to identify patients [read the full story…]
This systematic review of randomised trials found nine studies that investigated whether continuous glucose monitoring (CGM) compared with self-monitoring of blood glucose (SMBG) led to improved glycaemic control or a reduction in hypoglycaemic episodes. The reviewers combined the results of the study in a meta-analysis to measure the benefit of CGM compared with conventional treatment [read the full story…]
This randomised trial in Pediatric Diabetes looked at whether sending blood glucose levels over the internet to carers resulted in better glycemic control among adolescents with type 1 diabetes. However, the trial only had 70 participants, and around one third did not comply with the intervention, rendering the results almost meaningless. Although the authors carried [read the full story…]
